Zenara Pharma Pvt Ltd’s Post

The year 2024 marks a turning point for the biotechnology and #pharma industries, driven by transformative innovations and significant financial commitments. Key developments promise to reshape the landscape, fostering a future ripe with potential and growth. 📊 Key Highlights: 1️⃣ German #Biotech Sector Resilience: The German #Biotechnology Report 2024 reveals a 17% increase in capital raised in 2023 to €1.1 billion. Despite challenges in early-stage financing, the sector remains resilient with substantial venture capital investments and increased employment. 2️⃣ SciRhom's Breakthrough in Autoimmune Research: SciRhom, a German biotech startup, secured $70 million in Series A funding to advance its antibody #drugs targeting autoimmune diseases. Human trials for its lead candidate, SRS-878, are expected to begin this year, potentially transforming treatments for rheumatoid arthritis and inflammatory bowel disease. 3️⃣ #Germany's Medical Research Act: The new Medical Research Act allows private price negotiations for patent-protected medicines, fostering a more competitive market and encouraging further investment. 4️⃣ Corden Pharma - A Full-Service CDMO's Massive Investment: CordenPharma announced a €900 million investment over the next three years to expand GLP-1 peptide manufacturing in Europe and the US, meeting the growing global demand for diabetes and obesity treatments. 💡 Takeaway: Embrace advancements and strategic investments to thrive in 2024. The biotech and pharmaceutical sectors are brimming with possibilities, driven by innovation, regulatory changes, and significant capital inflows. Michael Quirmbach, CEO of CordenPharma, emphasizes: "We are honored by the trust our customers have placed in us to deliver expert outsourcing for large multiyear contracts, and our team is proud to contribute decades of peptide manufacturing experience towards these transformative new medicines." 🔗 Dive deeper into the articles for comprehensive insights 👇 Michael Schorpp, Liliana Montaño Herrera, Sonia H., Elizabeth A., Okan Ekinci, MD MBA, Gian Luca Satti, Promit Ray, PhD, Bojan Ljepoja, Artur Miguel Arsénio, Alexander Batz, Blagoy Georgiev, Izabel Siedle, Rameshgoud Ravelli, Thomas Flad, Jost Leemhuis, Artem Kolosovich, André Witt Join the conversation! Share your thoughts on these developments and how your organization is positioning itself for success in 2024. 💬 Share in the comments!

Happy New Year to all of my connections! I see a lot of posts talking about resolutions and hopes for the year ahead. While this is great, I prefer to reflect on the year past and join discussions of what the year ahead could look like collectively. 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜𝐚𝐥𝐥𝐲 𝐈 𝐰𝐚𝐧𝐭 𝐭𝐨 𝐭𝐚𝐥𝐤 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐥𝐨𝐛𝐚𝐥𝐥𝐲. It is no secret that 2023 was a low year for Clinical Research Investment. In fact, investment in biotech companies over the past two years has been a fraction of historical levels due to the global cost of borrowing, slowing down small and medium sized CRO's who rely on this type of business. This funding issue, paired with the large Covid 19 hiring drives that occurred in clinical operations teams globally in 2020 and 2021 created an overinflated market and has subsequently lead to companies having to make mass redundancies and re-structure to survive. Not a great year all in! The above overview of 2023 is not to scare people and foreshadow a similarly dreary market forecast in 2024. In fact, the U.S. Food and Drug Administration approved nearly 50% more novel drugs in 2023 than in 2022, putting it back on pace with historical levels. This is an improvement analysts and investors said could lead to increased investment in biotech firms, hopefully sparking more work for small and medium sized CRO's equipped to take it on. Although I do not think we will not see peak highs again in clinical research like we did in 2020, there is an expectation that 2024 will be the year we see the market re-balance to pre pandemic levels. I am interested to hear Clinical Research professionals in my network comment with their predictions for 2024 and the market we are likely to see. Do you agree with my analysis? If this is a topic you are interested to learn more about, join the discussion in the comments below.

Great free report from FT Live on the state of Obesity drugs. https://lnkd.in/es-gXbqd Some takeaways: 1 - Sales of weight loss drugs continue to surge ⬆ despite the significant cost to patients and lingering concern of healthcare systems and insurers about cost-effectiveness. 💸 ("Research by Goldman Sachs shows that the global market for anti-obesity medication could reach $100bn by 2030"!!) 2 - Alongside a huge existing consumer demand, there is a continued demand for further R&D in the space 💡 (new and existing competitors aim to develop therapeutics with fewer side effects or innovative delivery methods) 3 - With the expected weight loss and lowered calorie consumption, there will likely be impact to other sectors such as food & bev 🍔 4 - A noble cause... It's impossible to ignore the importance of this growing area of R&D, "A Harvard study shows nearly half of all Americans will be obese by 2030. This would have substantial financial implications, as 18 per cent of healthcare spending would be spent on conditions related to obesity." Interested to know where others see the future of obesity-related drugs!

With 'Health Industry Report India 2024' coming up in Forbes India, Executive Forecast sat down with Dr. Sanjeev Panchal to capture the journey of AstraZeneca in India for the past 45 years and its purpose to transform healthcare in the country. Read on to see how we are harnessing science to create novel therapies and vaccines, make them accessible FASTER to patients in India. Help people with chronic diseases live better, healthier lives. Redefine cancer care. And pioneer treatments for rare diseases.

Great post! A must read for anybody within the CGT ecosystem and indeed the wider biotech sector!

Great commentary Lee Buckler 👏 Here are my observations- 1️⃣There has been a cautious approach for investments for a while, elections playing a huge role in #India and in #US, also due to parts of #Europe and #MiddleEast who are now recovering after the regional crisis. 2️⃣ In some there was no constraints and #budgets were way over the board. 3️⃣ We need to design better #clinicaltrials for them to succeed. 4️⃣ #Allogeneic markets are riding on the wave of #autologous strategies and have to be realistic in the terms of approach and #approvals. 5️⃣ Progressive & aligned #Regulatoryframework is going to be the key to better healthcare of the future. ( Regulatory agencies are listening & drafting guidances to move this field forward, #USFDA and #EU taking leaps in recent times). 6️⃣ Local therapeutic hubs in each region is gaining momentum especially after #pandemic. Many #incubators have popped up spreading the #investments unevenly. 7️⃣ #Insurance companies need to see the big picture, they will save money in the long run by approving #CGTs and other evidence based #regenerative #applications. 8️⃣ If anyone wants to stay in the race an early dialogue with #regulators & #insurance companies will be critical. 9️⃣ #Novel #therapies and #technologies are the way forward but need #fasttracking processes and approvals. 🔟 #Harmonization in #Regulations #Standards #Processes #Approvals may help our #Patients to achieve the goal of #Health #Longevity #Vitality #Asa #Celltherapies #cellandgenetherapy #regenerativemedicine AABB #ABRM International Society of Blood Transfusion (ISBT) ISCT, International Society for Cell & Gene Therapy

Over the past 12 months or so, we have heard, seen and experienced the funding shortfalls across venture-backed companies not able to renew their #financing or complete their full funding rounds. We are now seeing this impacting larger #pharma budgets and strategic #investor activity who are being cautious with their funding. Some of this could be tied to hold-cash-until-the-US-election and/or better-to-be-overweighted-in-cash-over-summer #strategies. All this, of course, is in direct contrast to the incredible run the stock market is on driven largely by tech companies. Sector agnostic #investors are finding good returns in other industry segments. Committed #biotech investors, on the other hand, are being seduced with good clinical data and market success in other biopharma modalities compared to #cellandgene therapies (CGT) where autologous #celltherapies have faltered (temporarily in my opinion) to significantly increase market penetration, #genetherapies are being approved but struggling with reimbursement (particularly in Europe), the promise of CTs in large indications like auto-immune is far away and present an even large scale-up challenge, the translation of engineering other immune-cell types based on our CAR-T experience isn’t as easy as first (naively) thought, and the promise of allogeneic CGTs and/or CGT in solid tumors is so far not yet living up to perceived potential. In our opinion (Cell Therapy Group), this more restrictive financing environment for advanced therapies, is a retrenchment – a consolidation – a market-specific right-sizing of operations, investment, and strategy. What this is not, in our opinion, is a sign of any general biopharma shift away from a fundamental belief in the clinical and commercial potential of CGTs as one of the fastest growing pillars of health-care. That we are competing with the commercial potential of me-too obesity drugs and the hype around AI is a financial reality. That our clinical successes will and must be judged by the commercial viability of the products we bring to market is something to which we likely need to pay more attention. The smart people I’m surrounded by are already keenly aware of and building strategies around this to ensure tomorrow’s #CGTs are a better fit with the health economics we all face around the globe. We continue be very bullish on the potential of cell and gene therapies. What this is not is a belief that more of the same will drive different success. We are keenly aware that the CGTs of the 2030s – including the way we manufacture, deliver, and pay for them – will (and must) look very different than this generation of CGTs which have paved the way for the next evolution of commercially viable and clinical significant advanced therapies.

Patient experiences = Human Experiences Love these insights from our very own Pamela Walker Geddes and our client Matyas Lakatos 🙏🏼❤️ I loved our project with Novo Nordisk for diabetes - their ethos around patient centricity and experience aligned so strongly with our values and outlook too! Great insights, felt strongly both as a key partner, but also as the patient that I am these days :) #patientexperience #humanexperience #patientjourneys

🧬 MedGenome Acquires Stake in GenX Diagnostics to Strengthen Presence in East India. MedGenome, a leading genomics and clinical data-driven diagnostics company, has acquired a significant stake in GenX Diagnostics. This strategic move is aimed at bolstering MedGenome’s footprint in the eastern region of India. 💰 Acquisition Details: - MedGenome: Acquired a stake in GenX Diagnostics to enhance its service offerings and reach in East India. - GenX Diagnostics: A prominent diagnostics company known for its advanced genomic testing services. 🔍 Background: - MedGenome’s Vision: The acquisition aligns with MedGenome’s vision to expand its genomic diagnostics services across India, providing advanced and accessible healthcare solutions. - GenX Diagnostics’ Expertise: GenX Diagnostics brings to the table its expertise in high-quality diagnostic services, complementing MedGenome’s existing capabilities. 🚀 Expansion Plans: - Enhanced Services: The partnership will enable MedGenome to offer a broader range of genomic testing services in East India, catering to the growing demand for advanced diagnostics. - Market Reach: MedGenome aims to leverage GenX Diagnostics’ established presence to penetrate deeper into the regional market. 📈 Market Potential: - Growing Demand: The genomic diagnostics market in India is witnessing rapid growth, driven by increasing awareness and the need for personalized medicine. - Strategic Growth: This acquisition positions MedGenome strategically to capitalize on this growing market, offering state-of-the-art diagnostics services. 📅 Future Outlook: - Innovative Solutions: MedGenome plans to introduce innovative diagnostic solutions, enhancing the quality of healthcare services in East India. - Customer-Centric Approach: The company remains committed to delivering precise and timely diagnostic services, ensuring better health outcomes for patients. MedGenome’s acquisition of a stake in GenX Diagnostics marks a significant step towards expanding its presence and service offerings in East India. This strategic move underscores the company’s dedication to advancing genomic diagnostics and improving healthcare accessibility. MEDGENOME | Genx Diagnostics #MedGenome #GenXDiagnostics #Acquisition #GenomicDiagnostics #HealthcareExpansion #BusinessNews #StartupNews #MicroShots #NewsUpdates

Meet Emmanuel Akpakwu, Axmed’s co-founder and CEO. Who are the individuals behind this innovative venture, and what motivated them to embark on this journey? "This isn’t just about immediate impact—it’s about creating lasting change for decades to come," Emmanuel says. Growing up in a Low and Middle Income Country (LMIC), Emmanuel witnessed firsthand the devastating impact of inadequate access to quality, affordable medicines. Friends, family, and entire communities often faced impossible decisions between purchasing life-saving drugs or other essentials. The prevalence of substandard or counterfeit medicines only exacerbated these challenges, leading to poor treatment outcomes and unnecessary loss of life. Emmanuel's journey into the pharmaceutical industry revealed that manufacturers also struggle to reach LMIC markets due to fragmented healthcare systems and severe market failures. In some cases, life-saving medicines were marked up by as much as 400%, further hindering access. The lack of trust between healthcare providers and pharma manufacturers made things even worse, even as the need for affordable medicines in LMICs grew. Seeing these challenges, Emmanuel realized the transformative potential of Axmed. "By bringing together demand into one marketplace, we can empower buyers and attract high-quality manufacturers," he says. “Tackling the fragmentation and market failures could drastically reduce prices and ensure that patients in LMICs have reliable access to essential medicines,” Emmanuel further explains. “This isn't just about immediate impact—it's about creating lasting change for decades to come.” Emmanuel envisions a world where every patient in a low or middle-income country can easily and affordably get the life-saving medicines they need. "I want pharmaceutical companies to see the immense market and impact potential in these growth markets and prioritize them just as much as affluent nations," he shares. His goal is clear: to make high-quality, affordable medicines accessible to all, breaking down the barriers that have kept so many from the treatments they need. Got any questions for Emmanuel or the other founders of Axmed, Sofía Radley-Searle and Felix Ohnmacht, Ph.D.? Write them in the comments! #HealthcareAccess #Pharma #LMIC #AccessToMedicine